Frequency Therapeutics Inc (NASDAQ: FREQ) stock plunges in the premarket after reporting topline day-90 data from its Phase 2a study (FX-322-202) evaluating the company's lead product candidate FX-322 ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...
Top-Line Results Show Consistent Drug Entry in All Patients WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced top-line data from an exploratory clinical ...
Company to Host R&D Event on November 9th to Provide Detailed Review of Completed FX-322 Clinical Studies Supporting FX-322-208 Inclusion Criteria and Study Design LEXINGTON, Mass.--(BUSINESS WIRE)-- ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly ...
DEADLINE APPROACHING: Robbins LLP Reminds Investors with Substantial Losses of the Upcoming Lead Plaintiff Deadline in the Lawsuit Against Frequency Therapeutics, Inc. (FREQ) SAN DIEGO, CA & WOBURN, ...
In Follow-Up to Phase 1b Learning Study (FX-322-111), Some Subjects with Sensorineural Hearing Loss Show Increased Speech Perception Up to Twelve Months After Dosing LEXINGTON, Mass., September 22, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback